Abstract No : 4001
Indication : BRAF V600E metastatic Colorectal Cancer
Intervention : Encorafenib plus cetuximab with or without binimetinib
Company : Pfizer Inc.
Technology : Small molecule
Pts received triplet (n=224), doublet (n=220), or control (n=221). Median OS was 9.3 months (95% confidence interval [CI]:8.2, 10.8) for triplet and 5.9 months (95% CI:5.1-7.1) for control (hazard ratio [HR] (95% CI): 0.60 (0.47-0.75)). Median OS for doublet was 9.3 months (95% CI: 8.0-11.3) (HR vs. control: 0.61 (0.48-0.77). Confirmed ORR was 26.8% (95% CI: 21.1%-33.1%) for triplet, 19.5% (95% CI: 14.5%-25.4%) for doublet, and 1.8% (95% CI: 0.5%-4.6%) for control. Retrospective subgroup analyses suggested some pts may benefit more from triplet than doublet therapy (Table). Both triplet and doublet showed improved OS compared to control in all subgroups. Adverse events were consistent with prior analysis, with grade $3 adverse events in 65.8%, 57.4%, and 64.2% for triplet, doublet and control, respectively
The updated analysis of the BEACON CRC study confirmed that encorafenib + cetuximab with or without binimetinib improved OS and ORR in previously treated pts with BRAF V600E mCRC compared with standard chemotherapy.
After melanoma and NSCLC we can see CRC as another indication where some significant progress has been observed for BRAF V600E mCRC patients. Since encorafenib + cetuximab is already approved in refractory BRAF V600E mCRC setting we can see a new standard of care in these patients. As per the published results at ASCO 2020, encorafenib + cetuximab significantly improved OS, PFS and ORR relative to standared of care (control) in previously treated pts with BRAF V600E mCRC, a sub-population with historically dismal outcomes.